> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# A Malaria Antibody Cut Infant Infections by 78%. It Also Weakened Their Vaccine.
- URL: https://bioweek.com/a-malaria-antibody-cut-infant-infections-by-78-it-also-weakened-their-vaccine/
- Published: 2026-11-20T06:03:48.000Z
- Updated: 2026-11-20T11:55:43.000Z
- Description: The NIAID antibody L9LS cut infant malaria infections by 78% in Mali and weakened the response to the R21 vaccine, and the planned interaction study has been withdrawn. Inside the immunology that now shapes how malaria tools get sequenced.
- Author: BioWeek
- Tags: Science

Malaria's most advanced antibody shot works. The problem starts when the same infant is later given a malaria vaccine.

A monoclonal antibody developed by the National Institute of Allergy and Infectious Diseases, L9LS, protected infants in Mali against infection with the deadliest malaria parasite at 78% efficacy. In the same trial, a key antibody response to the R21 vaccine, given five months later, came out 20% to 30% lower than in infants who received a placebo. The follow-up study built to untangle that interference has now been [withdrawn](https://clinicaltrials.gov/study/NCT07208760?ref=bioweek.com), before it enrolled a single participant.

### The trial was designed to answer this question

The study, run in 2024 and 2025 at three sites in Mali, enrolled 180 healthy children aged 1 to 12 months. Half received a single 150 mg intramuscular dose of L9LS, half a saline placebo. The registry entry states the trial's [hypotheses](https://clinicaltrials.gov/study/NCT06461026?ref=bioweek.com) plainly: that L9LS would be safe and would not affect the immunogenicity of a later R21 series.

Results presented at the American Society of Tropical Medicine and Hygiene annual meeting showed the antibody was safe and well tolerated, with protective efficacy of [78%](https://www.miragenews.com/mali-trial-finds-malaria-antibody-protects-1780796/?ref=bioweek.com) against Plasmodium falciparum infection across Mali's six-month malaria season. The vaccine series followed on days 140, 168 and 196, three doses four weeks apart as WHO guidance and Malian practice call for. That is when the second finding surfaced. The R21 response was measurably weaker in children who had received L9LS.

The registered follow-up would have tested whether spacing solved it, dosing the antibody seven days, two months or four months before the first R21 shot. Its withdrawal note reads: "After careful review of R21 interaction data that recently became available from a previous L9LS infant study, the study team has made the decision to not move forward with this protocol."

### Why an antibody can blunt a vaccine

The offered explanation is narrow. L9LS binds weakly to the malaria protein contained in the R21 vaccine, even though that protein is not the antibody's primary target.

If that binding drove the result, the implication is structural. A vaccine works by presenting an antigen the immune system learns from. An antibody circulating at the time can meet that antigen first. The better it recognizes anything on the vaccine's surface, the more of the lesson it can intercept. That is a design constraint, not a manufacturing defect, and other malaria antibodies in early development are less likely to interfere with R21.

### What the 20% to 30% does not prove

Lower antibody titres are not the same as a broken vaccine. The researchers have not shown that the reduced response compromises the protection R21 actually delivers, and development of L9LS for children who have not completed the three-dose R21 series, those under roughly 2 to 3 years old, will not be considered until that question is answered.

R21's own record sets the bar. Its Phase 3 trial enrolled 4,800 children aged 5 months to 3 years across Mali, Burkina Faso, Tanzania and Kenya, and measured efficacy of [75%](https://www.tropicalmedicine.ox.ac.uk/news/r21-phase-iii-trial-results?ref=bioweek.com) at seasonal sites against first malaria episodes over the 12 months after vaccination, and 68% where transmission runs all year.

### Where the antibody still fits

The case for L9LS rests on speed, not durability. Malaria antibodies are meant to give near-immediate protection lasting about six months, which matters most before a child becomes eligible for vaccination at five months. Kassoum Kayentao, a physician-scientist at the University of Sciences, Techniques and Technologies in Bamako, said the team wanted to test it in infants as young as one month for that reason, because "children are not eligible for malaria vaccination until they are at least 5 months old, and that leaves them especially vulnerable."

Elsewhere the data remain encouraging. In a Phase 2 trial in Siaya county, western Kenya, two doses of L9LS produced protective efficacy of [42.7%](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2900258-8/abstract?ref=bioweek.com) against infection over 12 months in children aged 5 to 59 months, with no treatment-related serious adverse events. That figure covers a year of intense year-round transmission rather than one six-month season, a reminder of how much the setting shapes the number.

Researchers intend to keep testing L9LS in children still at risk after finishing the R21 series, since the vaccine is neither fully protective nor long lasting. Named uses include post-discharge prophylaxis for children hospitalized with severe malaria or anemia, an alternative to seasonal malaria chemoprevention once vaccination is complete, and in pregnancy.

The World Health Organization counted about 610,000 malaria deaths in 2024, most of them young African children, a toll that has barely budged in a decade as drug and insecticide resistance erodes the existing toolkit. Terrie Taylor, president of the ASTMH, said L9LS is "one of the most exciting malaria interventions now in development, and that makes it all the more important to evaluate interactions with other tools now in use."

What Mali adds is a sequencing problem the field did not face with one tool. Two interventions aimed at the same parasite can work against each other inside the same child, and the order and interval of delivery now belong in the clinical plan.